Obesity Drug Trials Should Be Shorter, Have Broader Endpoints, PhRMA Says
Executive Summary
The Pharmaceutical Research & Manufacturers of America is asking FDA to change its guidance on the development of weight loss drugs to allow shorter trials
You may also be interested in...
FDA Says No To Metabolic Syndrome; New Obesity Guidance Takes Hard Line
FDA currently views metabolic syndrome as "not necessarily" a distinct disease entity, according to the agency's draft guidance on obesity products
FDA Says No To Metabolic Syndrome; New Obesity Guidance Takes Hard Line
FDA currently views metabolic syndrome as "not necessarily" a distinct disease entity, according to the agency's draft guidance on obesity products
Weight-Loss Drug One-Year Data Enough For Safety and Efficacy – Cmte.
One-year trial data for weight-control drugs provides enough information to establish efficacy and safety for approval, a majority of FDA's Endocrinologic & Metabolic Drugs Advisory Committee concluded Sept. 8